BACKGROUND: Atomoxetine and escitalopram are potent and selective drugs approved for noradrenergic or serotonergic modulation of neuronal networks in attention-deficit hyperactivity disorder (ADHD) or depression, respectively. High-performance liquid chromatography (HPLC) methods still play an important role in the therapeutic drug monitoring (TDM) of psychopharmacological drugs, and coupled with tandem mass spectrometry are the gold standard for the quantification of drugs in biological matrices, but not available everywhere. The aim of this work was to develop and validate a HPLC method for neuroscientific studies using atomoxetine or escitalopram as a test drug. MATERIALS AND METHODS: A HPLC method from routine TDM determination of atomoxetine or citalopram in plasma was adapted and validated for use in neuroscientific research. Using photo diode array detection with UV absorption at 205 nm, the variation of internal standard within one chromatographic method enables separate drug monitoring for concentration-controlled explorative studies in healthy humans and patients with Parkinson's disease. RESULTS: The method described here was found to be linear in the range of 0.002 - 1.4 mg/L for atomoxetine and 0.0012 - 0.197 mg/L for escitalopram, with overall mean intra-day and inter-day imprecision and accuracy bias < 10% for both drugs. The method was successfully applied in concentration-controlled neuroimaging studies in populations of healthy humans and patients with Parkinson's disease. CONCLUSION: A simple, sensitive, robust HPLC method capable of monitoring escitalopram and atomoxetine is presented and validated, as a useful tool for drug monitoring and the study of pharmacokinetics in neuroscientific study applications.
BACKGROUND: Atomoxetine and escitalopram are potent and selective drugs approved for noradrenergic or serotonergic modulation of neuronal networks in attention-deficit hyperactivity disorder (ADHD) or depression, respectively. High-performance liquid chromatography (HPLC) methods still play an important role in the therapeutic drug monitoring (TDM) of psychopharmacological drugs, and coupled with tandem mass spectrometry are the gold standard for the quantification of drugs in biological matrices, but not available everywhere. The aim of this work was to develop and validate a HPLC method for neuroscientific studies using atomoxetine or escitalopram as a test drug. MATERIALS AND METHODS: A HPLC method from routine TDM determination of atomoxetine or citalopram in plasma was adapted and validated for use in neuroscientific research. Using photo diode array detection with UV absorption at 205 nm, the variation of internal standard within one chromatographic method enables separate drug monitoring for concentration-controlled explorative studies in healthy humans and patients with Parkinson's disease. RESULTS: The method described here was found to be linear in the range of 0.002 - 1.4 mg/L for atomoxetine and 0.0012 - 0.197 mg/L for escitalopram, with overall mean intra-day and inter-day imprecision and accuracy bias < 10% for both drugs. The method was successfully applied in concentration-controlled neuroimaging studies in populations of healthy humans and patients with Parkinson's disease. CONCLUSION: A simple, sensitive, robust HPLC method capable of monitoring escitalopram and atomoxetine is presented and validated, as a useful tool for drug monitoring and the study of pharmacokinetics in neuroscientific study applications.
Authors: Sarah R Delaney; Paul R V Malik; Cristiana Stefan; Andrea N Edginton; David A Colantonio; Shinya Ito Journal: Clin Pharmacokinet Date: 2018-12 Impact factor: 6.447
Authors: Alexander Schaefer; Inga Burmann; Ralf Regenthal; Katrin Arélin; Claudia Barth; André Pampel; Arno Villringer; Daniel S Margulies; Julia Sacher Journal: Curr Biol Date: 2014-09-18 Impact factor: 10.834
Authors: Samuel R Chamberlain; Adam Hampshire; Ulrich Müller; Katya Rubia; Natalia Del Campo; Kevin Craig; Ralf Regenthal; John Suckling; Jonathan P Roiser; Jon E Grant; Edward T Bullmore; Trevor W Robbins; Barbara J Sahakian Journal: Biol Psychiatry Date: 2008-11-20 Impact factor: 13.382
Authors: Zheng Ye; Charlotte L Rae; Cristina Nombela; Timothy Ham; Timothy Rittman; Peter Simon Jones; Patricia Vázquez Rodríguez; Ian Coyle-Gilchrist; Ralf Regenthal; Ellemarije Altena; Charlotte R Housden; Helen Maxwell; Barbara J Sahakian; Roger A Barker; Trevor W Robbins; James B Rowe Journal: Hum Brain Mapp Date: 2016-01-12 Impact factor: 5.038
Authors: Luca Passamonti; M Luijten; H Ziauddeen; I T S Coyle-Gilchrist; T Rittman; S A E Brain; R Regenthal; I H A Franken; B J Sahakian; E T Bullmore; T W Robbins; K D Ersche Journal: Psychopharmacology (Berl) Date: 2017-05-27 Impact factor: 4.530
Authors: Claire O'Callaghan; Frank H Hezemans; Rong Ye; Catarina Rua; P Simon Jones; Alexander G Murley; Negin Holland; Ralf Regenthal; Kamen A Tsvetanov; Noham Wolpe; Roger A Barker; Caroline H Williams-Gray; Trevor W Robbins; Luca Passamonti; James B Rowe Journal: Brain Date: 2021-09-04 Impact factor: 13.501
Authors: Frank H Hezemans; Noham Wolpe; Claire O'Callaghan; Rong Ye; Catarina Rua; P Simon Jones; Alexander G Murley; Negin Holland; Ralf Regenthal; Kamen A Tsvetanov; Roger A Barker; Caroline H Williams-Gray; Trevor W Robbins; Luca Passamonti; James B Rowe Journal: PLoS Comput Biol Date: 2022-05-09 Impact factor: 4.779